SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cheng MZ, Zaman G, Rawlinson SCF, Mohan S, Baylink DJ, Lanyon LE 1999 Mechanical strain stimulates ROS cell proliferation through IGF-II and estrogen through IGF-I. J Bone Miner Res 14:17421750.
  • 2
    Damien E, Price JS, Lanyon LE 1998 The estrogen receptor's involvement in osteoblasts' adaptive response to mechanical strain. J Bone Miner 13:12751282.
  • 3
    Damien E, Price JS, Suswillo RFL, Lanyon LE 2000 Mechanical strain stimulates proliferation through the estrogen receptor in males as well as females. J Bone Miner 15:21692177.
  • 4
    Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:14911494.
  • 5
    Migliaccio S, Davis VL, Gibson MK, Gray TK, Korach KS 1992 Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor. Endocrinology 130:26172624.
  • 6
    Zaman G, Cheng MZ, Jessop HL, White R, Lanyon LE 2000 Mechanical strain activates estrogen response elements in bone cells. Bone 27:233239.
  • 7
    Cheng MZ, Zaman G, Rawlinson SCF, Mohan S, Baylink DJ, Lanyon LE 1998 ROS cells proliferate in response to estrogen through IGF-I and mechanical strain through IGF-II. J Bone Miner Res 23:S561.
  • 8
    Gunnet JW, Granger K, Cryan E, Demarest KT 1999 Characterization of the progestin receptors in the human TE85 and murine MC3T3-E1 osteoblast-like cell lines. J Endocrinol 163:139147.
  • 9
    Chaudhary LR, Avioli LV 1998 Identification and activation of mitogen-activated protein (MAP) kinase in normal human osteoblastic and bone marrow stromal cells: Attenuation of MAP kinase activation by cAMP, parathyroid hormone and forskolin. Mol Cell Biochem 178:5968.
  • 10
    Takada J, Chevalley T, Baylink DJ, Lau KHW 1996 Dexamethasone enhances the osteogenic effects of fluoride in human TE85 osteosarcoma cells in vitro. Calcif Tissue Int 58:355361.
  • 11
    Beresford JN, Graves SE, Smoothly CA 1993 Formation of mineralized nodules by bone-derived cells in vitro—a model of bone formation. Am J Med Gen 45:163178.
  • 12
    McAllister RM, Gardner MB, Greene AE, Bradt C, Nichols WW, Landing BH 1971 Cultivation in vitro of cells derived from a human osteosarcoma. Cancer 27:397402.
  • 13
    Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M 1998 Molecular cloning and characterization of human estrogen receptor beta cx: A potential inhibitor of estrogen action in human. Nucleic Acids Res 26:35053512.
  • 14
    Van Wyk JJ, Russel WE, Underwood LE, Svoboda ME, Gillespie GY, Pledger WJ, Adashi EY, Balk SD 1986 Action of somatomedins on cell growth: Effect of selective nutralisation of somatomedin C (insulin-like growth factor I) with a monoclonal antibody. In: RaitiS, TolmanRA (eds.) Human Growth Hormone. Plenum Publishing Corp., New York, NY, USA, pp. 585599.
  • 15
    Yao D-L, West NR, Bondy CA, Brenner M, Hudson LD, Zhou J, Collins GH, Webster H 1995 Cryogenic spinal cord injury induces astrocytic gene expression of insulin-like growth factor I and insulin-like growth factor binding protein 2 during myelin regeneration. J Neurosci Res 40:647659.
  • 16
    Takana H, Asami O, Hayano T, Sasaki I, Yoshitake Y, Nishikawa K 1989 Identification of a family of insulin-like growth factor-II secreted by cultured rat epithelial-like cell line 18,54-SF: Application of a monoclonal antibody. Endocrinology 124:870877.
  • 17
    Suzuki T, Iwafuchi M, Takahishi H, Ikuta F, Nishikawa K, Tanaka H, Yanaihara N 1989 Immunocytochemical demonstration of IGF-II-like immunoreactivity in human paraganglioma of the craniocervical region. Virchows Arch A Pathol Anat 414:515521.
  • 18
    Kull FC, Jacobs S, Su YF, Svobuda ME, Van Wyk JJ, Cuatrecasas P 1983 Monoclonal antibodies to receptor for insulin and somatomedin C. J Biol Chem 258:65616566.
  • 19
    Rohlik QT, Adams D, Kull FC, Jacobs S 1987 An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture. Biochem Biophys Res Commun 149:276281.
  • 20
    Zaman G, Suswillo RFL, Cheng MZ, Tavares IA, Lanyon LE 1997 Early responses to dynamic strain change and prostaglandins in bone-derived cells in culture. J Bone Miner Res 12:769777.
  • 21
    Osborne CK, Monaco ME, Lippman ME, Kahn CR 1978 Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res 38:94102.
  • 22
    Dietrich JW, Paddcock DN 1979 In vitro effects of ionophore A23187 on skeletal collagen and noncollagen protein synthesis. Endocrinology 104:493499.
  • 23
    Mohan S, Baylink DJ 1995 Development of a simple valid method for the complete removal of insulin-like growth factor (IGF)-binding proteins from IGFs in human serum and other biological fluids—comparison with acid-ethanol treatment and C-18 Sep-Pak separation. J Clin Endocrinol Metab 80:637647.
  • 24
    Fitzsimmons RJ, Ryaby JT, Mohan S, Magee FP, Baylink DJ 1995 Combined magnetic-fields increase insulin-like growth factor-II in Te-85 human osteosarcoma bone cell cultures. Endocrinology 136:31003106.
  • 25
    Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K, Baylink DJ 1995 Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFPB-5 modulate IGF actions in bone cells. J Biol Chem 270:2042420431.
  • 26
    Mohan S, Bautista CM, Herring SJ, Linkhart TA, Baylink DJ 1990 Development of valid methods to measure insulin-like growth factor-I and factor-II in bone cell-conditioned medium. Endocrinology 126:25342542.
  • 27
    Snedecor GW, Cochran WG 1967 One-way classification. Analysis of variance. In: Statistical Methods, 6th ed. The Iowa State University Press, Ames, IA, USA, pp. 258298.
  • 28
    McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals 3 distinct classes of antiestrogens. Mol Endocrinol 9:659669.
  • 29
    Tzukerman MT, Esty A, Santisomere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by 2 functionally distinct intramolecular regions. Mol Endocrinol 8:2130.
  • 30
    Willson TM, Norris JD, Wagner BL, Asplin I, Baer P, Brown HR, Jones SA, Henke B, Sauls H, Wolfe S, Morris DC, McDonnell DP 1997 Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138:39013911.
  • 31
    Paech K, Webb P, Kuiper G, Nilsson S, Gustafsson JA, Kushner PJ, Scanlan TS 1997 Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites. Science 277:15081510.
  • 32
    Smith CL, Nawaz Z, Omalley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657666.
  • 33
    Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M 1997 Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: Functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun 236:140145.
  • 34
    Zajchowski DA, Webster L, Humm R, White FA, Simmons SJ, Bartholdi M 1997 Different estrogen receptor structural domains are required for estrogen- and tamoxifen-dependent anti-proliferative activity in human mammary epithelial cells expressing an exogenous estrogen receptor. J Steroid Biochem Mol Biol 62:373383.
  • 35
    Webb P, Lopez GN, Uht RM, Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway—potential origin for the cell specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443456.
  • 36
    Breuer B, Wallenstein S, Anderson R 1998 Effect of tamoxifen on bone fractures in older nursing home residents. J Am Geriatr Soc 46:968972.
  • 37
    Kenny AM, Prestwood KM, Pilbeam CC, Raisz LG 1995 The short-term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 80:32873291.
  • 38
    Kristensen B, Ejlertsen B, Mouridsen HT, Andersen KW, Lauritzen JB 1996 Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 39:321326.
  • 39
    Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ 1994 Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Int Med 154:25852588.
  • 40
    Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC 1988 Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least 2 years. Breast Cancer Res Treat 12:297301.
  • 41
    Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O 1998 Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83:11581162.
  • 42
    Resch A, Biber E, Seifert M, Resch H 1998 Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. Acta Oncologica 37:661664.
  • 43
    Turken S, Siris E, Seldin D, Flaster E, Hyman G, Lindsay R 1989 Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:10861088.
  • 44
    Powles T, Hickish T, Kanis JA, Tidy A, Ashley S 1996 Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:7884.
  • 45
    Kalu DN, Salerno E, Liu CC, Echon R, Ray M, Garzazapta M, Hollis BW 1991 A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner 15:109123.
  • 46
    Sibonga JD, Evans GL, Hauck ER, Bell NH, Turner RT 1996 Ovarian status influences the skeletal effects of tamoxifen in adult rats. Breast Cancer Res Treat 41:7179.
  • 47
    Li X, Takahashi M, Kushida K, Inoue T 1998 The less potent estrogenic effect of tamoxifen on bone in ovariectomized rats with established osteopenia. Calcif Tissue Int 62:502505.
  • 48
    Moon LY, Wakley GK, Turner RT 1991 Dose-dependent effects of tamoxifen on long bones in growing rats—influence of ovarian status. Endocrinology 129:15681574.
  • 49
    Ruenitz PC, Shen Y, Li M, Liang H, Whitehead RD, Pun S, Wronski TJ 1998 Specific bone-protective effects of metabolites/derivatives of tamoxifen and clomiphene in ovariectomized rats. Bone 23:537542.
  • 50
    Sato M, Rippy MK, Bryant HU 1996 Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10:905912.
  • 51
    Turner RT, Evans GL, Wakley GK 1993 Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats - Inhibition of indexes of formation and resorption. J Bone Miner Res 8:359366.
  • 52
    Williams DC, Paul DC, Black LJ 1991 Effects of estrogen and tamoxifen on serum osteocalcin levels in ovariectomized rats. Bone Miner 14:205220.
  • 53
    Goulding A, Gold E, Feng W 1992 Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin. Bone Miner 18:143152.
  • 54
    Ernst M, Schmid C, Froesch ER 1988 Enhanced osteoblast proliferation and collagen gene expression by estradiol. Proc Natl Acad Sci USA 85:23072310.
  • 55
    Fournier B, Haring S, Kaye AM, Somjen D 1996 Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones. J Endocrinol 150:275285.
  • 56
    Somjen D, Waisman A, Kaye AM 1996 Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in in vitro and in vivo. J Steroid Biochem Mol Biol 59:389396.
  • 57
    Tobias JH, Chambers TJ 1991 The effect of sex hormones on bone resorption by rat osteoclasts. Acta Endocrinol 124:121127.
  • 58
    Gallagher A, Chambers TJ, Tobias JH 1993 The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 133:27872791.
  • 59
    Spelsberg TC, Subramaniam M, Riggs LB, Khosla S 1999 The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol 13:819828.
  • 60
    Ernst M, Rodan GA 1991 Estradiol regulation of insulin-like growth factor-I expression in osteoblastic cells: Evidence for transcriptional control. Mol Endocrinol 5:10811089.
  • 61
    Turner RT, Backup P, Sherman PJ, Hill E, Evans GL, Spelsberg TC 1992 Mechanism of action of estrogen on intramembranous bone formation: Regulation of osteoblast differentiation and activity. Endocrinology 131:883889.
  • 62
    Wronski TJ, Cintron M, Doherty AL, Dann LM 1988 Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 123:681686.
  • 63
    Kalu DN, Liu CC, Solerno E, Hollis B, Echon R, Ray M 1991 Skeletal response of ovariectomized rats to low and high doses of 17β-estradiol. Bone Miner 14:175187.
  • 64
    McCarthy TL, Ji C, Shu H, Casinghino S, Crothers K, Rotwein P, Centrella M 1997 17β-Estradiol potently suppresses cAMP-induced insulin-like growth factor-I gene activation in primary rat osteoblast cultures. J Biol Chem 272:1813218139.
  • 65
    Robinson JA, Harris SA, Riggs LB, Spelsberg TC 1997 Estrogen regulation of human osteoblastic cell proliferation and differentiation. Endocrinology 138:29192927.
  • 66
    LeRoith D, Werner H, Beitner-Johnson D, Roberts CT 1995 Molecular and cellular aspects of the insulin-like growth factor-I receptor. Endocr Rev 16:143163.